MARKET NEWS


 

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial
Chiesi Global Rare Diseases Announces FDA Acceptance of BLA Filing for the Proposed Treatment of Alpha-Mannosidosis
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial
Pace Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy & Consulting Capabilities to the Biotechnology & Pharmaceutical Markets
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
Catalent Expands Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities

  FEATURED EDITORIAL


  COMPANY PROFILE

Evonik Health Care is a global innovation hub for the world’s leading life science companies. We support customers along the entire product cycle from early development to commercial manufacturing. Our system solutions are backed by the scientific excellence of our interdisciplinary and diverse teams. As an integrated CDMO, Evonik Health Care has been a leader for advanced drug delivery for many decades. It is also one of the world’s largest contract manufacturers of high potency APIs (HPAPIs) and active pharmaceutical ingredients (APIs) that require complex chemistry and multiple-step syntheses. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

SiSaf Announces Positive Preclinical Data for its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, recently announce positive data confirming safety and efficacy of its Bio-Courier next-generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an….

Aptose’s New G3 Formulation of Luxeptinib Boosts Bioavailability 

Aptose’s New G3 Formulation of Luxeptinib Boosts Bioavailability 

Aptose Biosciences Inc. recently announced the G3 formulation of luxeptinib, designed for rapid and efficient absorption, demonstrates approximately an 18-fold improvement in oral bioavailability….

Gerresheimer AG & Stevanato Group Announce Collaboration on the Development of an Innovative Ready-to-Use Vial Platform

Gerresheimer AG & Stevanato Group Announce Collaboration on the Development of an Innovative Ready-to-Use Vial Platform

Gerresheimer AG and Stevanato Group S.p.A. recently announced they have jointly developed a high-end Ready-to-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s….

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche

Good Therapeutics recently announced it has entered into a definitive merger agreement to be acquired by Roche. With this acquisition, Roche will gain….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

On-Demand Webinar: How to Safely Handle Your Antibody Drug Conjugate

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

In today’s fast-growing biopharma market, injectable medications have become a powerful driver of growth and innovation. Within that sector, industry leaders are increasingly focused on one key area: integrating a drug product and a delivery device. As the market expands …

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s latest whitepaper outlines the key parameters that drug developers should considering while evaluating oral delivery …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 21 – Gene Therapy
September 28 – API Synthesis